A Reversal for Newlink Genetics Corporation (NASDAQ:NLNK) Is Not Near. The Stock Has Rise in Shorts

July 18, 2017 - By test

 A Reversal for Newlink Genetics Corporation (NASDAQ:NLNK) Is Not Near. The Stock Has Rise in Shorts

Investors sentiment increased to 1.26 in 2016 Q4. Its up 0.43, from 0.83 in 2016Q3. It improved, as 10 investors sold NewLink Genetics Corp shares while 32 reduced holdings. 18 funds opened positions while 35 raised stakes. 13.75 million shares or 2.00% more from 13.48 million shares in 2016Q3 were reported.
Blackrock owns 2,506 shares. Art Advsrs Lc accumulated 46,200 shares. Blackrock Japan reported 1,818 shares. 145,800 were reported by Renaissance Tech Limited Liability Corporation. Alliancebernstein L P, a New York-based fund reported 38,400 shares. Moreover, Wells Fargo Mn has 0% invested in NewLink Genetics Corp (NASDAQ:NLNK). Vanguard Gru invested in 908,870 shares or 0% of the stock. Fenimore Asset Management invested in 12,321 shares. Us Bancorp De owns 0% invested in NewLink Genetics Corp (NASDAQ:NLNK) for 3,243 shares. Wall Street owns 0.74% invested in NewLink Genetics Corp (NASDAQ:NLNK) for 108,900 shares. 24,342 are owned by Acadian Asset Mngmt Lc. Baldwin Inv Mgmt Limited Liability Corp holds 17,000 shares or 0.07% of its portfolio. Millennium Management Ltd Limited Liability Company invested in 0.01% or 534,027 shares. Jpmorgan Chase & has invested 0% in NewLink Genetics Corp (NASDAQ:NLNK). Great West Life Assurance Can owns 2,048 shares or 0% of their US portfolio.

The stock of Newlink Genetics Corporation (NASDAQ:NLNK) registered an increase of 9.91% in short interest. NLNK’s total short interest was 4.86M shares in July as published by FINRA. Its up 9.91% from 4.42M shares, reported previously. With 1.84 million shares average volume, it will take short sellers 3 days to cover their NLNK’s short positions. The short interest to Newlink Genetics Corporation’s float is 24.7%.

The stock decreased 0.14% or $0.01 during the last trading session, reaching $7.37. About shares traded. NewLink Genetics Corp (NASDAQ:NLNK) has risen 49.90% since July 18, 2016 and is uptrending. It has outperformed by 33.20% the S&P500.

NewLink Genetics Corporation is a clinical-stage immuno-oncology firm focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $205.64 million. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. It currently has negative earnings. The Company’s biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells.

NewLink Genetics Corp (NASDAQ:NLNK) Ratings Coverage

Among 5 analysts covering NewLink Genetics (NASDAQ:NLNK), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. NewLink Genetics had 7 analyst reports since March 23, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Sunday, June 4 by Cantor Fitzgerald. Robert W. Baird initiated the stock with “Outperform” rating in Wednesday, March 23 report. Jefferies maintained it with “Hold” rating and $700 target in Thursday, June 8 report. SunTrust upgraded the stock to “Buy” rating in Thursday, March 30 report. As per Wednesday, May 11, the company rating was downgraded by SunTrust. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, July 10.

More notable recent NewLink Genetics Corp (NASDAQ:NLNK) news were published by: Prnewswire.com which released: “Biotech Stock Performance Review — NewLink Genetics, Ocera Therapeutics …” on July 11, 2017, also Globenewswire.com with their article: “NewLink Genetics to Host Its Second Quarter 2017 Financial Results Conference …” published on July 07, 2017, Seekingalpha.com published: “NewLink Genetics Is Still Undervalued, Despite The Disappointment From Navoximod” on June 12, 2017. More interesting news about NewLink Genetics Corp (NASDAQ:NLNK) were released by: Marketwatch.com and their article: “NewLink Genetics Corp. stock drops 28% on mid-stage results for melanoma drug” published on April 04, 2017 as well as Fool.com‘s news article titled: “A Surprising Disappointment Derails NewLink Genetics — What’s Next?” with publication date: June 19, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.